S L Douglas1,2, B J Daly3,1,2, N J Meropol1,2,4,3, A R Lipson1. 1. Case Comprehensive Cancer Center, Cleveland, OH. 2. Case Western Reserve University, Cleveland, OH. 3. Flatiron Health, an independent subsidiary of the Roche Group, New York, NY, U.S.A. 4. University Hospitals Cleveland Medical Center, Cleveland, OH.
Abstract
Background: Shared decision-making at end of life (eol) requires discussions about goals of care and prioritization of length of life compared with quality of life. The purpose of the present study was to describe patient and oncologist discordance with respect to goals of care and to explore possible predictors of discordance. Methods: Patients with metastatic cancer and their oncologists completed an interview at study enrolment and every 3 months thereafter until the death of the patient or the end of the study period (15 months). All interviewees used a 100-point visual analog scale to represent their current goals of care, with quality of life (scored as 0) and survival (scored as 100) serving as anchors. Discordance was defined as an absolute difference between patient and oncologist goals of care of 40 points or more. Results: The study enrolled 378 patients and 11 oncologists. At baseline, 24% discordance was observed, and for patients who survived, discordance was 24% at their last interview. For patients who died, discordance was 28% at the last interview before death, with discordance having been 70% at enrolment. Dissatisfaction with eol care was reported by 23% of the caregivers for patients with discordance at baseline and by 8% of the caregivers for patients who had no discordance (p = 0.049; ϕ = 0.20). Conclusions: The data indicate the presence of significant ongoing oncologist-patient discordance with respect to goals of care. Early use of a simple visual analog scale to assess goals of care can inform the oncologist about the patient's goals and lead to delivery of care that is aligned with patient goals. 2019 Multimed Inc.
Background: Shared decision-making at end of life (eol) requires discussions about goals of care and prioritization of length of life compared with quality of life. The purpose of the present study was to describe patient and oncologist discordance with respect to goals of care and to explore possible predictors of discordance. Methods:Patients with metastatic cancer and their oncologists completed an interview at study enrolment and every 3 months thereafter until the death of the patient or the end of the study period (15 months). All interviewees used a 100-point visual analog scale to represent their current goals of care, with quality of life (scored as 0) and survival (scored as 100) serving as anchors. Discordance was defined as an absolute difference between patient and oncologist goals of care of 40 points or more. Results: The study enrolled 378 patients and 11 oncologists. At baseline, 24% discordance was observed, and for patients who survived, discordance was 24% at their last interview. For patients who died, discordance was 28% at the last interview before death, with discordance having been 70% at enrolment. Dissatisfaction with eol care was reported by 23% of the caregivers for patients with discordance at baseline and by 8% of the caregivers for patients who had no discordance (p = 0.049; ϕ = 0.20). Conclusions: The data indicate the presence of significant ongoing oncologist-patient discordance with respect to goals of care. Early use of a simple visual analog scale to assess goals of care can inform the oncologist about the patient's goals and lead to delivery of care that is aligned with patient goals. 2019 Multimed Inc.
Entities:
Keywords:
Goals of care; decision-making; oncologists; patients; quality of life
Authors: Holly G Prigerson; Yuhua Bao; Manish A Shah; M Elizabeth Paulk; Thomas W LeBlanc; Bryan J Schneider; Melissa M Garrido; M Carrington Reid; David A Berlin; Kerin B Adelson; Alfred I Neugut; Paul K Maciejewski Journal: JAMA Oncol Date: 2015-09 Impact factor: 31.777
Authors: Neal J Meropol; Brian L Egleston; Joanne S Buzaglo; Al B Benson; Donald J Cegala; Michael A Diefenbach; Linda Fleisher; Suzanne M Miller; Daniel P Sulmasy; Kevin P Weinfurt Journal: Cancer Date: 2008-12-15 Impact factor: 6.860
Authors: Jonathan Bergman; Eric Ballon-Landa; Steven E Lerman; Lorna Kwan; Carol J Bennett; Mark S Litwin Journal: Am J Hosp Palliat Care Date: 2015-08-09 Impact factor: 2.500
Authors: Robert Gramling; Kevin Fiscella; Guibo Xing; Michael Hoerger; Paul Duberstein; Sandy Plumb; Supriya Mohile; Joshua J Fenton; Daniel J Tancredi; Richard L Kravitz; Ronald M Epstein Journal: JAMA Oncol Date: 2016-11-01 Impact factor: 31.777
Authors: Sara L Douglas; Polly Mazanec; Amy R Lipson; Kim Day; Eric Blackstone; David L Bajor; Joel Saltzman; Smitha Krishnamurthi Journal: JCO Oncol Pract Date: 2021-01
Authors: Anne Brédart; Aude Rault; Johanna Terrasson; Etienne Seigneur; Leanne De Koning; Elisabeth Hess; Alexia Savignoni; Paul Cottu; Jean-Yves Pierga; Sophie Piperno-Neumann; Manuel Rodrigues; Carole Bouleuc; Sylvie Dolbeault Journal: JMIR Res Protoc Date: 2022-01-12
Authors: Gina Tuch; Chandrika Sanapala; Supriya G Mohile; Paul R Duberstein; Enrique Soto-Perez-de-Celis; Huiwen Xu; Eva Culakova; Marie Flannery; Reza Yousefi-Nooraie; Ronald M Epstein; Colin McHugh; Valerie Aarne; Hannah Kim; Jodi Geer; Mark A O'Rourke; Nicholas J Vogelzang; Kah Poh Loh Journal: Oncologist Date: 2021-08-11